Gland Pharma shares fell after a significant block deal involving Fosun Pharma Industrial. The company’s VSEZ facility received zero USFDA observations after a recent inspection. Gland Pharma reported strong Q1FY27 results with increased profit and revenue. Its CDMO and B2B businesses showed substantial year-on-year growth. The pharma stock has gained significantly year-to-date.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.